Data from autologous peripheral blood progenitor cell (PBPC) transplant recipients were used for cost analysis and modelling so as to link the main intervention procedures and clinical events to resource use and costs. This cohort consisted of 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years) who underwent a first transplant between August 1994 and May 1997. The main indications for transplantation were non-Hodgkin's lymphomas (47%), multiple myeloma (30%) and Hodgkin's lymphomas (15%). The course of a patient during the whole transplant procedure was modelled using a Markov chain of six states of health: (1) mobilisation and recovery of PBPC; (2) post-mobilisation phase; (3) conditioning and transplant; (4) critical haematological reconstitution; (5) noncritical haematological reconstitution; (6) death. The probability of transition between the different health states, together with the estimated costs, were the input for the Markov model. The model also managed transition probabilities depending both on the current health state and on various demographic, clinical and procedure-related covariates unique to the patient. The expected time spent in each clinical state and the expected total cost were, therefore, estimated. This analysis gave an actual total cost per transplanted patient of $26 600 (95% range: $24 700 to $43 500) while mean duration was 197 days. The expenses for in-hospital stay accounted for 80% of the costs. Both the probability of staying in the different states, and the consequent cost were dependent on the number of CD34-positive cells collected, the phase and the type of the disease, the subset of patients (either children or adults), and the post-transplant G-CSF prophylaxis. The sensitivity of the estimates to alternative assumptions was studied, and the method of comparing alternative future scenarios by the model was explored.
Easier acquisition, faster recovery of bone marrow function 1 and lower costs [2] [3] [4] led to widespread adoption of peripheral blood progenitor cells (PBPC) instead of bone marrow for autologous transplantation. Despite the enormous advances that made PBPC transfusions substantially safer than in the past, this procedure still carries a series of risks, and supportive therapies are needed to reduce morbidity and mortality, thus making the transplant process variable in terms of clinical events and resource use.
In the issue of optimal allocation of resources for health care, economic analysis has become a fundamental part of technology assessment. PBPC transplantation underwent economic evaluation in the United States, 1, 3 France, 5-11 the Netherlands, 2, 12 Spain, 13, 14 Canada, 4 Italy 15 and United Kingdom. 16 Most of the studies, some retrospective and others prospective, modelled clinical events and outcomes along with costs. Recently, Bredeson et al 4 reported a model of the transplant costs, accounting for the amount of G-CSF used for mobilisation, the number of aphereses performed and the rescue product manipulation.
In this study, we performed a cost analysis of PBPC transplantation at an Italian research hospital, and developed a Markov model to simulate the entire procedure by the probabilities of key events and costs. The model was designed so as to supply implications for costs of potential future changes in the probability of specific clinical events, such as might result from different treatment protocols or from different policies of resource use.
Patients and methods

Patient cohort and information sources
Data were used for all autologous PBPC transplant recipients who underwent a first transplant between August 1994 and May 1997. The procedure was carried out at two transplant centres of our University Hospital, the Institute of Haematology and the Department of Paediatrics. The study cohort included 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years), 79% of patients being aged 20 to 60 years. The main indications for transplantation were non-Hodgkin's lymphomas (30 patients: 47%), multiple myeloma (19 patients: 30%) and Hodgkin's lymphomas (10 patients: 15%). The remaining five patients (8%) had relatively rare diseases. Table 1 shows the main characteristics of the patients, according to the transplantation group. The mobilisation regimen consisted of high-dose antineoplastic therapy in 57 patients (89%) and combined chemotherapy in seven (11%) ( Table 1) . PBPC were collected by 10-12 litre leukaphereses on a COBE Spectra (COBE Laboratories, Lakewood, CO, USA), without any CD34-positive cell selection. Patients received PBPC transplant if the overall CD34-positive cell count of the PBPC product was Ͼ1.8 ϫ 10 6 /kg patient weight. Patients were conditioned pre-transplant with one of several high-dose regimens, depending on their diagnosis and prior treatment history. Most patients received CVB (cyclophosphamide, carmustine and etoposide) for Hodgkin's lymphoma or melphalan, etoposide and total body irradiation for low-grade non-Hodgkin's lymphoma. Patients with multiple myeloma were conditioned with BEAM (carmustine, etoposide, cytarabine and melphalan) or BEAC (carmustine, cyclophosphamide, etoposide and cytarabine) regimen. Platelet transfusions were given when the platelet count was Ͻ15 ϫ 10 9 /l. This threshold did not hold if the patient was febrile or bleeding. Granulocyte colony-stimulating factor (G-CSF) was not routinely scheduled following PBPC re-infusion: the utilisation of G-CSF did not follow a local protocol, but varied among physicians and years of patient care, thus mirroring physicians' propensities, both subjective and evidence-based. Patients were nursed on a standard hospital ward with HEPA filters but without laminar air flow rooms. During the recovery phase following autograft, patients were managed with a common protocol for prophylaxis. Patients were to receive trimethoprim-sulfamethoxazole twice weekly for Pneumocystis pneumonia prophylaxis, and oral acyclovir for HSV prophylaxis starting from admission. Febrile neutropenia (T Ͼ38°C and ANC Ͻ0.5 ϫ 10 9 /l) was to be treated with either a combination of gentamycin and teicoplanin or single agent therapy with third generation cephalosporin until neutrophil engraftment (ANC Ͼ0.5 ϫ 10 9 /l) and defervescence. Patients were discharged when all the following criteria were fulfilled: (1) ANC Ͼ0.5 ϫ 10 9 /l; (2) unsupported platelet count Ͼ15 ϫ 10 9 /l; (3) no fever and off systemic antibiotics/antimycotics for 72 h.
All the data were collected retrospectively on the basis of the transplant unit clinical records and a research database.
Methods for assessing cost
Cost analysis was restricted to direct medical costs to the hospital, since the primary perspective of the analysis was that of the hospital. Resource utilisation, in physical quantities, was obtained from detailed analysis of individual patient records, while monetary valuation of the physical quantities was based on an estimation of the observed unit costs. Some cost items (such as parenteral nutrition) were deliberately excluded in order to simplify data collection, because a previous study 2 had already shown that they represented a very small proportion of total costs (less than 2%) and had no econometric role.
The costs per unit of medical resources are reported in Table 2 . Room costs were obtained from the hospital's accounting system: total yearly costs of consumable supplies, hotel cost, labour costs of the department/ transplantation unit and depreciation of equipment (depreciation rate of 20%) were included. Top-down methodology was used to add overheads to per diem room costs. Professional service costs were based on current billing patterns and reimbursement.
For collection, processing and storage of PBPC, the cost was adapted from a previous estimate for patients treated in our hospital. Drug prices were the purchase prices obtained from our pharmacy department. To take into account problems related to drug packaging, the assumption was made that every vial opened was completely used, and that the drug package used was the closest to the prescribed dose. Laboratory and diagnostic costs were derived from a weight system established by the Italian Laboratory Society and unitary costs assessed for each diagnostic unit. Blood products were determined as per unit cost for the trans- fusional centre to supply these products as determined by the hospital's accounting system. Costs were reported in 1994 Italian lira corrected by a 3% yearly inflation rate and converted to US$ (1700 lira approximately equals 1 US$). No discounting was used, because the study includes only short-term results. Costs were separately analysed for adults and children because of different care organisation.
The Markov model
The course of a patient during the whole transplant procedure was modelled using a Markov process. 17 A Markov process consists of health states and transitions among them, given that a basic assumption holds: ie that the probability of any state transition is independent of the previous history of state transitions. The transplant experience of an individual patient was viewed as the passage through a sequence of five states of health and eventually death. This is illustrated in Figure 1 . At any time t, a patient may be classified into one of the following states: (1) mobilisation and recovery of PBPC, ie from the first day of hospital stay or from the time of the first examination done in provision of the transplantation, until the day of the last collection of PBPC; (2) post-mobilisation phase, ie from the day after the last collection procedure up to the day before the beginning of conditioning regimen; (3) conditioning and transplant, ie from the first day of conditioning regimen to the day of PBPC infusion; (4) critical haematological reconsti- tution, ie from the day after PBPC infusion to the day of discharge from the hospital; (5) non-critical reconstitution, ie from the day after discharge until the last event related to transplantation. At the end of transplantation, patients enter the adsorbing state 'out of transplantation' and are withdrawn from the Markov process. 'Dead' is a possible adsorbing state for each of the transplantation states. Each time period of the model represents a day. It was assumed that transplanted individuals progress through the stages of transplantation irreversibly and sequentially. The probabilistic structure of the model was specified by the probability of transition between the different states. The model recognised that the transition probabilities depended not only on the current health state, but also on various demographic, clinical and procedure-related variables (covariates) unique to the patient. Covariates considered in the model included: age (children or adult), sex, type and stage of disease, haemoglobin at transplantation inception, number of aphereses performed, amount of CD34-positive cells collected and G-CSF prophylaxis.
To estimate the transition probabilities, (t), we assumed they were time-invariant until a lag time T from the entry in that state, where T represented the minimum number of days a patient spent in the specific state. The transition probability was derived from the following formula:
where h(t) represented the hazard function of exit from one state which was estimated by applying Cox proportional hazards modelling technique, under the assumptions of proportional hazards, multiplicative covariates and conditional independence of transitions.
To assess the distribution of total transplantation costs and duration according to the distribution of covariates, a large sample of patients was simulated by Monte Carlo analysis. 18 This technique allows plotting the probability distribution resulting from a multi-way sensitivity analysis when all the uncertain variable values of the model are varied simultaneously. Transplantation projects under alternative assumptions, that is for different covariate values, were then analysed.
Data analysis
Patients' characteristics, clinical events and cost factors were compared using 2 test for categorical data, Student's t-test for normally distributed quantitative variables, and Mann-Whitney non-parametric test for the other quantitative variables (including costs). Because the distribution of patients' total costs was positively skewed, we carried out all analyses using the logarithm of total transplantation costs. A computer program (DATA software for Windows, TreeAge Software, Boston, MA, USA) set up the Markov model.
Results
Procedural and clinical events
Of the 64 patients who were entered for PBPC transplantation, none died during the transplantation period. 19.4% of the patients received three or more apheresis procedures (median number, 2); children received more apheresis procedures (mean, 2.05) than adults (mean, 1.87), although the difference was not significant due to the small number of children included in the study. The number of CD34-positive cells collected varied from 1 to 17 ϫ 10 6 /kg (mean 9.18). The median time to reach 0.5 ϫ 10 9 /l ANC after transplantation was 11 days (range, 9 to 17). The median time to reach an unsupported platelet count of 30 ϫ 10 9 /l was 7.8 days (range, 1 to 17 days). Platelet transfusion requirement was from 0 to 59 units (median, 7), and red cell transfusion requirement was from 0 to 6 units (median, 1).
During post-transplant haematological reconstitution, 53% of the patients (73% of patients with myeloma and 42% of patients with lymphoma) were supported by G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA), 5 g/kg/day s.c. for a median duration of 7 days. Patients supported by G-CSF engrafted more rapidly than did unsupported patients (10.34 days vs 12.83 days for the ANC to reach 0.5 ϫ 10 9 /l; P Ͻ 0.01), but the duration of their critical recovery was similar (6.39 vs 6.48; P Ͼ 0.05). This holds true independently of the disease. Twenty-nine episodes of infection (positive cultures or clinical manifestations) were observed, only one of which was in a child.
There was a significant difference (P Ͻ 0.003) between the median number of days for the ANC to reach 0.5 ϫ 10 9 /l in children (median, 9 days), and in adults (median, 11 days). The number of days to reach an unsupported platelet count of 30 ϫ 10 9 /l was significantly shorter (P Ͻ 0.004) in the children (mean, 8.42 days) compared with the adults (mean, 10.87 days). On the contrary, fever duration in the critical haematological recovery phase was significantly longer in children than in adults (5.3 median days in children vs 2.66 in adults; P у 0.028). There was no difference, however, in time to erythroid engraftment, and platelet or red cell transfusion requirement.
Costs
The analysis gave an actual overall cost per transplant patient of $26 600 (Lit 45.3 million) with a 95% range from $24 700 to $43 500. In 8% of the cases the cost was higher than $47 000. Hospitalisation accounted for the majority of costs over the full period of PBSC transplantation (80%). Almost all of the remaining costs were due to laboratory and radiological investigations (10% and 3%, respectively). Growth factors, antineoplastic chemotherapy and antibiotics accounted for 3%, 1.5% and 1.2%, respectively, of the total cost. Leukapheresis and freezing contributed 2.8% and 0.7%, respectively. The mean cost of PBPC transplantation was significantly lower in the adult group, where the mean cost was $25 600, with a range from $18 000 to $52 800, than in paediatric patients, where the mean cost of transplantation was $33 760, with a range from $21 760 to $62 940 (P = 0.02). This was mainly due to a greater caution in discharge of children, mainly because of difficult feeding and significantly prolonged fever (5.3 median days in children vs 2.66 in adults; P = 0.028). Among the adult patients, there was a significant difference in costs (P Ͻ 0.0001) between patients with multiple myeloma and those with lymphoma ($27 350 vs $23 647).
The Markov model
The duration of the PBPC transplantation procedure had a mean of 197 days and the 95% range was from 56 to 389 days. The actual mean proportion of time spent in each of the states of the model is presented in Table 3 . On average, for 83% of the time patients were in the state of 'postmobilisation' or 'non-critical haematological reconstitution' after transplantation. This was due to the fact that our model included waiting time after collection to reinfusion of PBPC and the time for late-occurring events after transplantation. During the whole transplantation procedure, time spent in hospital ranged from 29 to 54 days (median, 35 days), ie from 9 to 60% of the whole transplantation duration. As a mean, 43% of this time was spent for 'mobilisation', 16% for 'conditioning and transplant', and 41% for 'critical haematological reconstitution'. 'Mobilisation and recovery', 'conditioning and transplant' and post-transplant 'critical haematological reconstitution' phases, accounted for 80% of the cost. The Cox proportional hazard model also verified the independence of each transition rate from the duration of earlier phases.
By predicting costs through the model, total cost per simulated transplant patient was of $26 720, and expected transplantation duration was 197.5 days. As such, the model tended to overestimate cost by 0.45%, and duration by 0.25%. To check cost distribution among patients, we performed a Monte Carlo simulation (1000 trials). The skews of cost distribution accurately mirrored the observed distribution.
By coupling transition probabilities to covariates, the Cox proportional hazards model recognised a number of significant determinants of the transition hazard. The list of covariates, baseline hazard, ie when the covariate values were equal to zero, regression coefficients and minimum sojourn time for any state were shown in Table 4 . Both a higher number of CD34-positive cells collected and young age (in a child) favoured a long stay in the 'mobilisation' phase. The impact of age was mainly due to the higher number of apheresis collections performed in paediatric a The transition to the subsequent state is not allowed before the minimum sojourn time has elapsed, while after it the transition rate is made of a baseline hazard (h 0 ) modified by independent parameters. b If the increasing of the parameter values causes an increasing overall hazard rate, that is a shorter stay in that phase, then its regression coefficient will be positive. The opposite is also true: the regression coefficients are negative for those parameters. which lead to a longer stay in the phase preceding the transition. c Daily cost indicates the median observed cost for 1 day spent by a generic patient in a specific phase. Each cycle of the Markov model is valued the specific daily cost.
patients. Early stage of the disease at mobilisation increased the hazard of staying in the 'post-mobilisation phase': patients transplanted at first remission had a lower chance of being transplanted earlier than patients at the second remission or in relapse. Equally, transplantation of lymphoma patients produced a longer 'conditioning and transplantation' duration than transplantation of myeloma patients. Having received G-CSF prophylaxis following autografting, being a lymphoma patient, and being an adult, were all independently associated with shorter stay in the 'critical haematological recovery' phase. In a scenario analysis, modelled costs of alternative assumptions were calculated (Table 5 ). Transplantation in children costs 13.2% more than transplantation in adults, and myeloma patients cost 5% more than lymphoma patients. Fourteen days of prophylaxis with G-CSF reduced the whole cost by 13% with respect to the cost of not using the drug. Collecting a high number of CD34-positive cells reduced the total cost of transplantation by 7%.
Discussion
The aim of this work was first to analyse the costs of PBPC transplantation at an Italian research hospital and then to provide a model that supported economic assessment on the basis of patients' epidemiology, intervention procedures and clinical outcomes.
The cost of PBPC transplantation resulting from our analysis averaged $26 600 with a 95% range from $24 700 to $43 500. Cell mobilisation, conditioning regimen and post-transplant critical haematological reconstitution phases accounted for 80% of the cost, and the number of days spent in hospital was the major cost factor, accounting for 80% of the total cost of the procedure. These results were comparable to those reported from $20 162) , that is from 27% to 31% lower than our mean cost, and the most significant differences were in both the cost of the rescue product and use of post-reinfusion resources. This cost difference was counted mainly by the unit cost of in-hospital stay, which was 10 times lower than ours. On the contrary, the overall transplantation cost we observed was 30% lower than the $45 792 cost reported in a European randomised clinical trial based on US estimates of costs. 1 However, no great differences were reported in time to platelet recovery, time to neutrophil recovery and hospitalisation days. Major differences were in the unit cost both of hospital stay and of PBPC graft. Thus, in general, cost variations can be attributed more to differences in overheads, structure of social medicine and local practice patterns rather than to the outcomes of the transplantation procedure.
In this work a model was designed that enabled us to link costs and duration of the progressive phases composing a transplant procedure, so as to predict the cost of different strategies directly affecting the length of stay in any of the phases. By virtue of its iterative nature, a Markov process seemed ideally suited to the investigation of a process such as a management policy for patients with multistate disease. Statistical probabilities were used to indicate the likelihood of transition from one state to another occurring within a specified interval of time. Through Cox analysis it was possible to identify those components of a transplantation protocol affecting transition probabilities and thus the stateduration and costs. The results of the analysis demonstrated that patient-specific characteristics and the results of transplantation procedures are influential factors for both the duration and cost of specific transplantation phases. Children had a better haematological reconstitution after transplantation but, in spite of this, they had a longer in-hospital phase after transplantation. This was probably due to a greater caution in discharging children, mainly because of difficult feeding and a significantly longer period of fever (5.3 median days in children vs 2.66 in adults; P = 0.028). Equally, patients with lymphoma had a shorter conditioning phase and critical haematological reconstitution phase than patients with myeloma. CD34-positive cell collection overall proved to be a powerful predictor of the duration and costs of haemopoietic recovery phase. This is in agreement with the predictive value of the CD34-positive cell number for myeloid reconstitution after transplantation. 19 Myeloid growth factor after PBPC reinfusion had an influential effect on recovery phase duration and costs that were independent from the number of CD34-positive cells collected. This was in agreement with the data reported by Tarella et al 15 documenting that G-CSF reduced morbidity with a cost containment of approximately 16%.
The results of this analysis demonstrated the feasibility of an effective cost prediction for a complex procedure by the use of simple clinical data. Therefore, case mix, mobilisation regimen and apheresis requirements can now be taken into account when planning cost-containment interventions. As such, given invariant medical outcomes, performing transplantation only in the population of patients with a disease in the early phase, ie at first remission, would decrease the expected cost of the post-mobilisation phase by reducing the length of stay in that phase. Moreover, our study confirmed that routine support of haematological recovery with G-CSF would lead to substantial cost containment, mainly due to earlier discharge. 15 In the same way, different policies should be constructed for the paediatric and the adult setting of haematological care, since in the former patients are more fragile and most procedures require higher costs. Since there is no general agreement about the optimal number of CD34-positive cells needed in order to obtain optimal haemopoietic engraftment, 20 the model offered a way to assess the cost of the transplantation procedure by varying the number of CD34-positive cells.
The use of such modelling may allow centres beginning a transplant program, or centres analysing the costs of their program, to finely estimate the costs of various approaches. Moreover, high-cost patients may be identified sufficiently early in their hospital stay to institute patient-specific costcontainment interventions. As the field continues to undergo rapid evolution, direct economic studies will become more difficult to perform with significant patient numbers. Similarly, the external validity of any single institution approach will be increasingly limited. One of the advantages of using a natural history model based on simulations is its ability to accommodate many potential interventions with minimal reprogramming. A further advantage of Markov models is their capability to synthesise multiple outcomes, such as the duration of the procedure and costs. This issue implies a certain superiority of time modelling on classical statistical prediction tools, which, however, are still necessary for inputting data into the Markov model.
Some limitations in this study should be acknowledged: our model has not yet been tested on a separate sample of patients, neither inside the same institution, nor outside it. Moreover, generalisation to other settings needs great caution, since our hospital is a research hospital and provides a high standard of care, demonstrated also by the fact that no death was reported in the transplantation period of the study. Indeed, the model described here was designed so as to handle statistical variability, which makes it suitable to some institution-specific modifications.
